OTCMKTS:UCBJF UCB (UCBJF) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free UCBJF Stock Alerts $119.90 0.00 (0.00%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$119.90▼$119.9050-Day Range$87.10▼$122.0052-Week Range$69.70▼$122.00Volume800 shsAverage Volume203 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisAnalyst ForecastsChartFinancialsHeadlinesSEC FilingsShort Interest Get UCB alerts: Email Address Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About UCB Stock (OTCMKTS:UCBJF)UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.Read More UCBJF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart UCBJF Stock News HeadlinesMarch 22, 2024 | finance.yahoo.comUCB Convening Notice to the General Meeting of the Shareholders 2024March 7, 2024 | realmoney.thestreet.comUCB price target raised by EUR 13 at BarclaysMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.February 28, 2024 | msn.comUCB SA reports FY resultsFebruary 10, 2024 | marketwatch.comStocks A-ZFebruary 4, 2024 | msn.comInvestors growing more bullish on SMID cap biotech stocksNovember 14, 2023 | msn.comUCB launches newly approved psoriasis drug Bimzelx in USNovember 11, 2023 | finance.yahoo.comPost Hoc Analysis Showed CIMZIA® (Certolizumab Pegol) Resulted in Meaningful Efficacy for RA Patients with High Levels of Rheumatoid Factor (RF)March 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.November 10, 2023 | finance.yahoo.comUCB Presents New Five-Year Data on BIMZELX® (bimekizumab-bkzx) in Ankylosing Spondylitis at ACR Convergence 2023October 18, 2023 | finance.yahoo.comBIMZELX® Approved by the U.S. FDA for the Treatment of Adults with Moderate-to-Severe Plaque PsoriasisOctober 18, 2023 | finance.yahoo.comUCB announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the treatment of adults with generalized myasthenia gravisOctober 13, 2023 | finance.yahoo.comUCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023October 12, 2023 | finance.yahoo.comPhase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis SuppurativaJune 27, 2023 | finance.yahoo.comFDA Approves Rystiggo: The Only Treatment for Two Most Common Subtypes of Generalized Myasthenia Gravis in AdultsFebruary 22, 2023 | finance.yahoo.comChina Anti-Rheumatic Drug Markets Report 2022-2027 Featuring Pfizer, F. Hoffmann-La Roche, UCB S.A., Eli Lilly and Company, & AbbVie Inc.October 20, 2022 | finance.yahoo.comUCB SA (UCBJF)April 25, 2022 | finance.yahoo.comHere's Why Momentum in UCB SA (UCBJF) Should Keep goingMarch 31, 2022 | msn.comWhat Makes UCB SA (UCBJF) a Good Fit for "Trend Investing"March 25, 2022 | finanznachrichten.deUCB SA/NV - CONVENING NOTICE TO THE GENERAL MEETING OF SHAREHOLDERS 2022February 7, 2022 | seekingalpha.comBiogen signs licensing deal with Xbrane for potential biosimilar to CimziaJanuary 23, 2022 | finance.yahoo.comZGNX Jan 2022 7.000 callJanuary 21, 2022 | msn.comWhy Zogenix Flew Higher Before Leveling Off This WeekJanuary 19, 2022 | markets.businessinsider.comUCB to Buy Epilepsy-Focused Zogenix In $1.9B Deal: See The HighlightsNovember 5, 2021 | finance.yahoo.comUCB Showcases Key Rheumatology Data at ACR Convergence 2021October 20, 2021 | finance.yahoo.comUCB to license its AI technology that improves identification of Osteoporosis to ImageBiopsy LabOctober 16, 2021 | msn.comBRIEF-UCB SA Gives An Update On U.S. FDA Review Of Biologics License Application (BLA) For BimekizumabSee More Headlines Receive UCBJF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for UCB and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:UCBJF CUSIPN/A CIK1290640 Webwww.ucb.com Phone(322) 559-9999Fax32-2559-9900Employees8,703Year Founded1928Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.29 Current Ratio1.13 Quick Ratio0.79 Sales & Book Value Annual Sales$5.27 billion Price / SalesN/A Cash Flow$7.90 per share Price / Cash Flow15.17 Book Value$50.52 per share Price / Book2.37Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta0.55 Social Links 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Jean-Christophe Tellier (Age 65)CEO & Executive Director Comp: $4.45MMs. Sandrine Dufour CFA (Age 58)Executive VP, CFO & Chief Corporate Development Dr. Kirsten Lund-Jurgensen Ph.D. (Age 64)Executive Vice President of Supply & Technology Solutions Dr. Dhavalkumar D. Patel M.D. (Age 63)Ph.D., Executive VP & Chief Scientific Officer Ms. Denelle J. Waynick Johnson J.D. (Age 57)Executive VP & General Counsel Mr. Jean-Luc Fleurial (Age 59)Executive VP & Chief Human Resources Officer Prof. Iris Low-Friedrich (Age 64)Executive VP & Chief Medical Officer Mr. Emmanuel Caeymaex (Age 55)Executive VP of Immunology Solutions & Head of US Ms. Caroline VancoillieChief Accounting Officer, Head of Group Finance & CFO of Patient Value FunctionsAntje WitteHead of Investor RelationsMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors UCBJF Stock Analysis - Frequently Asked Questions Should I buy or sell UCB stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for UCB in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" UCBJF shares. View UCBJF analyst ratings or view top-rated stocks. How have UCBJF shares performed in 2024? UCB's stock was trading at $87.10 at the beginning of the year. Since then, UCBJF stock has increased by 37.7% and is now trading at $119.90. View the best growth stocks for 2024 here. How do I buy shares of UCB? Shares of UCBJF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:UCBJF) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding UCB SA Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.